{
    "organizations": [],
    "uuid": "38c492bea95c0b847cbd7513638613350f5ec116",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-approves-b/brief-astrazeneca-says-us-fda-approves-bydureon-for-use-with-basal-insulin-in-patients-with-type-2-diabetes-with-inadequate-glycemic-control-idUSASC09UNZ",
    "ord_in_thread": 0,
    "title": "BRIEF-AstraZeneca Says US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - AstraZeneca PLC:\n* US FDA APPROVES BYDUREON FOR USE WITH BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES WITH INADEQUATE GLYCEMIC CONTROL\n* 7 STUDY RESULTS SHOWED SIGNIFICANT HBA1C REDUCTION WHEN BYDUREON WAS ADDED TO INSULIN GLARGINE THERAPY VERSUS INSULIN GLARGINE ALONEâ€‹ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-03T20:03:00.000+03:00",
    "crawled": "2018-04-04T12:29:50.030+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "astrazeneca",
        "plc",
        "u",
        "fda",
        "approves",
        "bydureon",
        "use",
        "basal",
        "insulin",
        "patient",
        "type",
        "diabetes",
        "inadequate",
        "glycemic",
        "control",
        "study",
        "result",
        "showed",
        "significant",
        "hba1c",
        "reduction",
        "bydureon",
        "added",
        "insulin",
        "glargine",
        "therapy",
        "versus",
        "insulin",
        "glargine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}